Abstract
Neonatal hypoglycaemia is one of the most common biochemical findings in the newborn period and is an important cause of brain injury. However, despite being so common there is no consensus regarding the glucose threshold concentration at which treatment for asymptomatic neonatal hypoglycemia should be initiated. Neurodevelopmental outcome studies in infants after neonatal hypoglycaemia have been mostly observational, comparing newborns with and without hypoglycaemia, and these studies have reported inconsistent results. Due to the lack of evidence and consensus, there is no consensus screening or treatment protocol, and this leads to both overtreatment and undertreatment with adverse effects on newborn health, bonding of motherchild, and health care costs. Therefore, well-designed clinical trials are required to devise the appropriate treatment strategies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
